Vinge represents Altor Fund V in connection with its investment in H2 Green Steel. The investment has been carried out in connection with H2 Green Steel's series B round totalling approx. EUR 190 million. Investors participating in the capital raise included, in addition to Altor, inter alia AMF, GIC, Swedbank Robur Alternative Equity, FAM and IMAS Foundation.

H2 Green Steel was founded in 2020 with the ambition to accelerate the decarbonization of the steel industry, using green hydrogen. Steel, which is one of the world’s largest carbon dioxide emitters, is the company’s first business vertical. H2 Green Steel is headquartered in Stockholm, Sweden, with its first green steel plant under development in Boden, northern Sweden.

Vinge's team consisted mainly of Christina Kokko, Johan Larsson, Carl Fredrik Wachtmeister, Linus Adolfsson (M&A), Lisa Hörnqvist, Elis Allmark (Commercial Agreements), Johan Cederblad (Environment), Kristoffer Larsson (Real Estate), Julia Löfqvist (Compliance), Kamyar Najmi (Banking and Finance), Axel Lennartsson (IP), Ebba Svenburg (Employment), Sara Dahlros Sköld and Julia Hagelberg (project assistants).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025